
## **KLRF1** Antibody

PACO19915



Product Information	
Size:	Protein Background:
50ul	Dual specificity protein kinase which acts as an essential component of the MAP kinase
Reactivity:	signal transduction pathway. Essential component of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7, is
Human	the one of the only known kinase to directly activate the stress-activated protein
Source:	kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 and MAP2K7/MKK7 both activate the JNKs by phosphorylation, but
Rabbit	they differ in their preference for the phosphorylation site in the Thr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation of the Tyr residue and MAP2K7/MKK7
lsotype:	for the Thr residue. The phosphorylation of the Thr residue by MAP2K7/MKK7 seems to be the prerequisite for JNK activation at least in response to proinflammatory cytokines,
lgG	while other stimuli activate both MAP2K4/MKK4 and MAP2K7/MKK7 which
Applications:	synergistically phosphorylate JNKs. MAP2K4 is required for maintaining peripheral lymphoid homeostasis.
Elisa, ihc	Gene ID:
Recommended dilutions:	KLRF1
ELISA:1:2000-1:5000, IHC:1:50-1:200	Uniprot
	Q9NZS2
	Synonyms:
	killer cell lectin-like receptor subfamily F, member 1
	Immunogen:
	Synthetic peptide of human KLRF1.
	Storage:

-20° C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol



The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using PACO19915(KLRF1 Antibody) at dilution 1/25, on the right is treated with synthetic peptide. (Original magnification: x—200).

The image on the left is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using PACO19915(KLRF1 Antibody) at dilution 1/25, on the right is treated with synthetic peptide. (Original magnification: x—200).